Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease

Kim, Il Young; Kim, June Hyun; Kim, Min Jeong; Lee, Jun Young; Hwang, Cheol Gu; Rhee, Harin; Song, Sang Heon; Seong, Eun Young; Lee, Soo Bong

doi:10.1007/s11255-018-1967-x

Cited by 9 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our data still showed low levels of platelets and serum albumin. In addition, we observed a higher rate of inadequate response to EPO through an elevated EPO/Hb ratio in patients with CKD [34].…”

Section: Plos Onementioning

confidence: 62%

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Background Anemia is common in chronic kidney disease (CKD) and is associated with outcomes. In addition, serum soluble Fas (sFas) levels are related to anemia and erythropoietin (EPO) resistance. Objectives Firstly, to compare clinical data and serum levels of sFas, EPO, and pro-inflammatory markers between patients with non-dialytic CKD (NDD-CKD) and healthy subjects. Subsequently, to compare and evaluate the relationship of serum EPO, sFas levels with anemia, and outcomes in patients with NDD-CKD over a long follow-up period. Methods We performed a retrospective study in 58 NDD-CKD patients compared with 20 healthy subjects on complete blood count, kidney function, serum EPO, sFas, and inflammatory markers (CRP, IL- 6, and IFN-γ) at baseline. We then compared the same baseline data between patients with NDD-CKD who evolved to anemia and those who did not have anemia over the follow-up. We also evaluated the frequency of outcomes in patients with CKD with higher sFas levels. Finally, we performed a multivariate analysis of factors associated with CKD anemia. Results There were lower eGFR and Hb but higher serum inflammatory markers, sFas levels, sFas/eGFR, and EPO/Hb ratios in patients with NDD-CKD. Comparatively, on the other hand, NDD-CKD patients with anemia had lower eGFR but were older, had more diabetes, and had higher sFas/ eGFR, EPO/Hb ratios, and serum levels of IL-6 and sFas than NDD-CKD without anemia for an extended period. In addition, there was an association in a multivariate analysis of diabetes, age, and sFas levels with kidney anemia. Furthermore, there were higher frequencies of outcomes in increased serum sFas levels. Conclusion As an elective risk factor, serum sFas levels, in addition to age and diabetes, were independently associated with kidney anemia for an extended period. Thus, more studies are necessary to analyze the proper relationship of sFas with kidney anemia and its outcomes and therapy in CKD.

show abstract

Section: Plos Onementioning

confidence: 62%

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the present study had several strengths. First, serum 1,25(OH) 2 D levels were measured instead of those of 25(OH)D. The levels of 1,25(OH) 2 D reflect the true biological activity of vitamin D because this form binds to VDR, whereas 25(OH)D levels reflect the vitamin D stores because it is the main circulating form of vitamin D 34 . We think that the results of this study are more physiologically relevant than those of previous studies that measured 25(OH)D levels.…”

Section: Discussionmentioning

confidence: 99%

1,25-dihydroxyvitamin D deficiency is independently associated with cardiac valve calcification in patients with chronic kidney disease

Kim

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Cardiac valve calcification is highly prevalent in patients with chronic kidney disease (CKD). Low vitamin D levels are associated with vascular calcification in CKD. However, the association between vitamin D levels and cardiac valve calcification is unknown. A total of 513 patients with pre-dialysis CKD were included in this cross-sectional study. Aortic valve calcification (AVC) and mitral valve calcification (MVC) were assessed using two-dimensional echocardiography. The associations between AVC and MVC and baseline variables were investigated using logistic regression analyses. In multivariable analysis, serum 1,25(OH)2D level was independently associated with AVC (odds ratio [OR], 0.87; P < 0.001) and MVC (OR, 0.92; P < 0.001). Additionally, age, diabetes, coronary heart disease, calcium × phosphate product, and intact parathyroid hormone levels were independently associated with AVC and MVC. Systolic blood pressure was independently associated with AVC. A receiver-operating characteristic (ROC) curve analysis showed that the best cutoff values of serum 1,25(OH)2D levels for predicting AVC and MVC were ≤ 12.5 and ≤ 11.9 pg/dl, respectively. Serum 1,25(OH)2D deficiency is independently associated with AVC and MVC in patients with CKD, suggesting that serum 1,25(OH)2D level may be a potential biomarker of AVC and MVC in these patients.

show abstract

“…Low 1,25(OH)2D expression is associated with nutritional deficiency or endogenous resistance of EPO in patients with CKD, and often contributes to anemia (88). However, these associations are not affected by inflammatory status or secondary hyperparathyroidism (89).…”

Section: Fgf23 and Epomentioning

confidence: 99%

Crosstalk of fibroblast growth factor 23 and anemia‑related factors during the development and progression of CKD (Review)

et al. 2021

View full text Add to dashboard Cite

Fibroblast growth factor 23 (FGF23) plays an important role in the development of chronic kidney disease-mineral bone disorder (CKD-MBD). Abnormally elevated levels of 1,25-dihydroxyvitamin D cause osteocytes to secrete FGF23, which subsequently induces phosphaturia. Recent studies have reported that iron deficiency, erythropoietin (EPO) and hypoxia regulate the pathways responsible for FGF23 production. However, the molecular mechanisms underlying the interactions between FGF23 and anemia-related factors are not yet fully understood. The present review discusses the associations between FGF23, iron, EPO and hypoxia-inducible factors (HIFs), and their impact on FGF23 bioactivity, focusing on recent studies. Collectively, these findings propose interactions between FGF23 gene expression and anemia-related factors, including iron deficiency, EPO and HIFs. Taken together, these results suggest that FGF23 bioactivity is closely associated with the occurrence of CKD-related anemia and CKD-MBD.

show abstract

Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease

Abstract: The serum 1,25(OH)D level exhibited significant associations with anemia, EPO deficiency, and endogenous EPO resistance in CKD patients. These associations were independent of secondary hyperparathyroidism and inflammation status.

Cited by 9 publications

References 22 publications

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease

1,25-dihydroxyvitamin D deficiency is independently associated with cardiac valve calcification in patients with chronic kidney disease

Crosstalk of fibroblast growth factor 23 and anemia‑related factors during the development and progression of CKD (Review)

Contact Info

Product

Resources

About